Advantages and challenges of oestrogen-free hormonal contraception

Current Medical Research and Opinion

Volumn 26, Issue 8, 2010, Pages 1947-1955

  Ahrendt, Hans Joachim ^a   Adolf, Daniela ^b   Buhling, Kai J ^c  

^a Practice for Gynecology and Clinical Research   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Contraceptive; Dysmenorrhoea; Premenstrual syndrome; Progesterone only pill

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO;

BIBLIOGRAPHIC DATABASE; BREAST TENDERNESS; DRUG EFFICACY; DYSMENORRHEA; EDEMA; ESTROGEN THERAPY; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; MEDLINE; MENSTRUAL CYCLE; MENSTRUAL MIGRAINE; MONOTHERAPY; NAUSEA; PREMENSTRUAL SYNDROME; REVIEW;

CONTRACEPTION; CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; HUMANS; MENSTRUATION DISTURBANCES; PROGESTERONE; RISK FACTORS;

EID: 77954723003     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.493088     Document Type: Review

References (72)

1. United Nations. World Contraceptive Use 2007. 2008. Available at: http://www.un.org/esa/population/publications/contraceptive2007/ contraceptive2007.htm [Last accessed 3 November 2009]
2. Boyce J, Fawcett JW, Noall EW. Coronary thrombosis and Conovide. Lancet 1963;1:111
3. Jick H, Dinan B, Herman R, et al. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978;240:2548-52
4. Mann JI, Vessey MP, Thorogood M, et al. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J 1975;2:241-5
5. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997;78:1-6
6. Sartwell PE, Stolley PD. Oral contraceptives and vascular disease. Epidemiol Rev 1982;4:95-109
7. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612-18
8. Thorogood M, Vessey MP. An epidemiologic survey of cardiovascular disease in women taking oral contraceptives. Am J Obstet Gynecol 1990; 163:274-81
9. Ahrendt HJ, Karck U, Pichl T, et al. The effects of an oestrogen-free, deso-gestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care 2007;12:354-61
10. Fischer MA. Implanon: a new contraceptive implant. J Obstet Gynecol Neonatal Nurs 2008;37:361-8
11. Rowlands S. New technologies in contraception. Br J Obstet Gynaecol 2009; 116:230-9
12. Pfizer Inc. Depo-Provera Contraceptive Injection. Patient Information, US. 2006. Available at: http://media.pfizer.com/files/products/ppi-depo-prover- a-contraceptive.pdf [Last accessed 3 November 2009]
13. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50:S1-195
14. Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008;34:237-46
15. Trussell J, Hatcher RA, Cates W Jr, et al. Contraceptive failure in the United States: an update. Stud Fam Plann 1990;21:51-4
16. Chi I. The safety and efficacy issues of progestin-only oral contraceptives-an epidemiologic perspective. Contraception 1993;47:1-21
17. Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75 mg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception 2005;71:8-13
18. Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 1999;14:982-5
19. Collaborative Study Group on the Desogestrel-containing Progestogen-only pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micro-grams/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 1998;3:169-78
20. Grimes DA, Lopez LM, O'Brien PA, et al. Progestin-only pills for contraception. Cochrane Database Syst Rev (Online) 2010:CD007541
21. What do your patients really think about the pill? Contracept Rep 1995;6:8
22. Peipert JF, Gutmann J. Oral contraceptive risk assessment: a survey of 247 educated women. Obstet Gynecol 1993;82:112-17
23. Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 2005;193:636-49
24. Silberstein SD. Hormone-related headache. Med Clin North Am 2001; 85:1017-35
25. Hatcher RA, Guillebaud J. The pill: combined oral contraceptives. In: Hatcher RA et al. (eds.) Contraceptive Technology, 17th edn. New York: Ardent Media, Inc., 1998:405-60
26. Oddens BJ, Arnolds HT, Van Maris MG, et al. The dynamics of oral contraceptive use in The Netherlands 1990-1993. Adv Contracept 1994; 10:167-74
27. Ahrendt HJ, Apetauer I. Improvement of oestrogen-related symptoms with a desogestrel-only contraceptive among women who experienced oestrogen-related symptoms using combined oral contraceptives. Eur J Contracept Reprod Health Care 2008;13:102-3
28. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev (Online) 2008:CD003987
29. Oddens BJ, Visser AP, Vemer HM, et al. Contraceptive use and attitudes in Great Britain. Contraception 1994;49:73-86
30. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006;108:428-41
31. Bieglmayer C, Hofer G, Kainz C, et al. Concentrations of various arachi-donic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995;9:307-12
32. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev (Online) 2001:CD002120
33. Rosenwaks Z, Seegar-Jones G. Menstrual pain: its origin and pathogenesis. J Reprod Med 1980;25:207-12
34. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desoges-trel-containing low-dose oral contraceptive. Contraception 2002;66:393-9
35. Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev (Online) 2005:CD004695
36. Lurie S, Borenstein R. The premenstrual syndrome. Obstet Gynecol Surv 1990;45:220-8
37. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 2003;28:55-99
38. Sundström Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health 2003; 6:23-41
39. Straneva PA, Maixner W, Light KC, et al. Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol 2002;21:358-67
40. Epperson CN, Haga K, Mason GF, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002;59:851-8
41. Andersch B, Hahn L. Premenstrual complaints II. Influence of oral contraceptives. Acta Obstet Gynecol Scand 1981;60:579-83
42. Kutner SJ, Brown WL. Types of oral contraceptives, depression, and premenstrual symptoms. J Nerv Ment Dis 1972;155:153-62
43. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993;37:195-202
44. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology 1993;18:273-81
45. Hellberg D, Claesson B, Nilsson S. Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynaecol Obstet 1991;34:243-8
46. Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Progesterone Study Group. Br J Gen Pract 1995;45:589-93
47. Couturier EG, Bomhof MA, Neven AK, et al. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-8
48. Allais G, Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutical strategies. Neurol Sci 2004;25(Suppl. 3):S229-31
49. Headache Classification Subcommittee of the International Headache Society (IHS). The International Classification of Headache Disorders, 2nd edn (ICHD II). Cephalalgia 2004;24(Suppl. 1):1-160
50. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6
51. Ahrendt HJ, Kleinschmidt S, Kropf S, et al. Prä ventive Wirkung hormoneller Kontrazeptiva im Langzyklus bei menstrueller Migrä ne. Frauenarzt 2007; 48:2-7
52. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117: 93-102
53. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-102
54. Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-96
55. Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric 2008;11:355-63
56. Allais G, Gabellari IC, De Lorenzo C, et al. Oral contraceptives in migraine. Expert Rev Neurother 2009;9:381-93
57. Allais G, Gabellari IC, Mana O, et al. Migraine and stroke: the role of oral contraceptives. Neurol Sci 2008;29(Suppl. 1):S12-S14
58. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2005/2006). London: Faculty of Family Planning and Reproductive Health Care, 2006
59. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54
60. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7
61. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921
62. Baillargeon JP, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005;90:3863-70
63. Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004;164:741-7
64. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000;284:72-8
65. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-93
66. International Collaborative Post-marketing Surveillance of Norplant. Post-marketing surveillance of Norplant contraceptive implants: II. Non-reproductive health. Contraception 2001;63:187-209
67. World Health Organization. Cardiovascular disease and use of oral and inject-able progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998;57:315-24
68. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999;354: 1610-11
69. Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;46(Suppl. 1):S31-S31
70. Vieira CS, Ferriani RA, Garcia AA, et al. Use of the etonogestrel- releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 2007;22:2196-201
71. Porter C, Rees MC. Bleeding problems and progestogen-only contraception. J Fam Plann Reprod Health Care 2002;28:178-81
72. Organon Laboratories Limited. Cerazette: Summary of product characteristics. 2008. Available at: http://emc.medicines.org.uk/medicine/10098 [Last accessed 3 November 2009]